| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/05/2008 | WO2008067115A2 Selective immunodepletion of endogenous stem cell niche for engraftment |
| 06/05/2008 | WO2008067025A2 Oncolytic adenoviruses and uses thereof |
| 06/05/2008 | WO2008066964A2 Compositions and methods for inducing or inhibiting activities of selected human cells |
| 06/05/2008 | WO2008066890A2 Polyamides with tail structures |
| 06/05/2008 | WO2008066776A2 Methods for treating hypercholesterolemia |
| 06/05/2008 | WO2008066744A2 Methods and compositions for treating and preventing spinal cord injury and other neuronal disease or injury |
| 06/05/2008 | WO2008066658A2 Engineered cellular pathways for programmed autoregulation of differentiation |
| 06/05/2008 | WO2008066626A2 METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR |
| 06/05/2008 | WO2008066483A1 Use of nalp5 in methods for diagnosis and therapy of parathyroid related disorders |
| 06/05/2008 | WO2008066057A1 Control of cell proliferation targeted for iqgap3 |
| 06/05/2008 | WO2008066032A1 Lymphangiogenesis inhibitory factor |
| 06/05/2008 | WO2008065752A1 Immunotherapeutic agent containing dirna as active ingredient |
| 06/05/2008 | WO2008065429A1 Method for delivering gene therapy vectors to the optic nerve head |
| 06/05/2008 | WO2008065369A2 A bleomycin preparation for use against skin tumours |
| 06/05/2008 | WO2008064540A1 Compositions comprising adeno-associated virus-mediated anti-angiogenic factor-hgfk1 and uses thereof |
| 06/05/2008 | WO2008064451A1 Poxviridae treatment comprising tap-1 and/or tap-2 as a molecular adjuvant |
| 06/05/2008 | WO2007135570A8 Pink1 deficient animals, screening methods, and related therapeutics |
| 06/05/2008 | US20080134352 Using vector transformation to generate recombinant rodents for use as heterologous gene expression models |
| 06/05/2008 | US20080132464 Selective induction of apoptosis to treat ocular disease |
| 06/05/2008 | US20080132462 Administering an agent which inhibits the expression or activity of p46 Shc and/or p52 Shc; determining whether an agent inhibits the phosphorylation of p46 Shc or p52 Shc |
| 06/05/2008 | US20080132461 Introducing RNA which targets the mRNA of the gene for degradation into the cell or organism; maintaining the cell or organism, maintaining the cell or organism under conditions under which degradation of the mRNA occurs |
| 06/05/2008 | US20080132448 Conserved neisserial antigens |
| 06/05/2008 | US20080131976 Novel G protein coupled receptor protein, DNA its ligand |
| 06/05/2008 | US20080131901 Using methylase expression as diagnostic/prognostic indicator of cell proliferative dsorders |
| 06/05/2008 | US20080131889 Novel human genes and gene expression products: II |
| 06/05/2008 | US20080131884 Tubulin Mutation Diagnostic |
| 06/05/2008 | US20080131871 Using vector comprisng nucleotide sequences coding cell binding elements to transform cells and identify lymphocyte response modulators |
| 06/05/2008 | US20080131459 Vaccines, diagnostic agents; expression vectors for heterologous genes; deletion mutants, pseudorevertants, transfectants |
| 06/05/2008 | US20080131448 Using interleukin receptor as tool in treatment cell proliferative disorders; antitumor agents |
| 06/05/2008 | US20080131422 Brain protein specific immunoglobulin for use in diagnosis, prevention and treatment of alzheimer's disease |
| 06/05/2008 | US20080131407 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 06/05/2008 | US20080131403 Recombinant Adeno-Associated Virus Expressing human Antisense Gene Cyp2j2 and Its Preparation Methods |
| 06/05/2008 | US20080131400 Vector system |
| 06/05/2008 | US20080131399 Using interferon alpha chimera to treat and prevent cell proliferative and viral diseases |
| 06/05/2008 | US20080131371 Oligonucleotide Non-Viral Delivery Systems |
| 06/05/2008 | US20080131370 For prophylaxis or treatment of apoptosis or inflammation-associated disease, diabetes, or chronic obstructive pulmonary disease |
| 06/05/2008 | CA2693178A1 Myostatin inhibition for enhancing muscle and/or improving muscle function |
| 06/05/2008 | CA2673757A1 Poxviridae treatment |
| 06/05/2008 | CA2670563A1 Methods for treating hypercholesterolemia |
| 06/04/2008 | EP1927665A2 Methods and kits for diagnosing and treating b-Cell chronic lymphocytic leukemia (B-CLL) |
| 06/04/2008 | EP1927660A2 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions |
| 06/04/2008 | EP1927598A1 Vaccine |
| 06/04/2008 | EP1927368A2 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 06/04/2008 | EP1493033B1 Use of sc6 for diagnosis and treatment of breast carcinoma |
| 06/04/2008 | EP1456357B1 Pluripotent embryonic-like stem cells derived from teeth and uses thereof |
| 06/04/2008 | EP1448089A4 Devices and methods for the restoration of a spinal disc |
| 06/04/2008 | EP1370693B1 Amplified cancer gene wip1 |
| 06/04/2008 | EP1192182B1 Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
| 06/04/2008 | EP1019082B2 Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 06/04/2008 | EP0946199B1 TGF beta 1-RESPONSIVE CELLS FROM BONE MARROW |
| 06/04/2008 | EP0920505B1 Mammalian cell surface antigens; related reagents |
| 06/04/2008 | CN101190946A Recombination plasmodium falciparum circumsporozoite surface protein and its preparation method and use |
| 06/04/2008 | CN101190944A Human cytokine and use thereof |
| 06/04/2008 | CN101190335A Gene therapy medicine for fibrotic disease |
| 06/04/2008 | CN100392087C Flavivirus vaccine delivery system |
| 06/04/2008 | CN100392085C Vaccines |
| 06/04/2008 | CN100392083C DNA encoding ovine adenovirus (OAV 287) and its use as a viral vector |
| 06/04/2008 | CN100392082C Conserved neisserial antigens |
| 06/04/2008 | CN100391970C DNA sequence and recombinant production of the grass pollen allergen Phl p4 |
| 06/04/2008 | CN100391544C The E type DNA vaccine of Chlamydi trachomatis and its preparation methods and applications |
| 06/04/2008 | CN100391543C Non-viral gene delivery system |
| 06/04/2008 | CN100391542C Composition for delivering genes to antigen presenting cells of the skin and its use |
| 06/04/2008 | CN100391534C Modulation of smooth muscle cell proliferation |
| 06/03/2008 | US7381711 Substances for preventing and treating autoimmune diseases |
| 06/03/2008 | US7381710 Nucleic acid comprising a sequence encoding promyelocytic leukemia retinoic acid receptor alpha and a non-immunosuppressive inducer of tumor cell apoptosis which is arsenic; all-trans, 9-cis or 13-cis retinoic acid; or 4 allopurinol-l-ribonucleoside |
| 06/03/2008 | US7381709 Method of expressing foreign gene in kidney |
| 06/03/2008 | US7381708 Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye |
| 06/03/2008 | US7381526 Assays for drug discovery based on microcompetition with a foreign polynucleotide |
| 06/03/2008 | US7381422 Mixing cationic surfactant, a polyoxyethylene and polyoxypropylene block copolymer and a polynucleotide at a temperature below the cloud point of said block copolymer to form a mixture; cold filtering the mixture to produce a sterile formulation |
| 06/03/2008 | US7381421 Liposomes |
| 06/03/2008 | CA2558659C Genetically engineered canary poxvirus-based vaccine strain |
| 06/03/2008 | CA2279846C Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 06/03/2008 | CA2203809C Recombinant adenovirus and methods of use thereof |
| 06/03/2008 | CA2160016C Method of forming oligonucleotides |
| 05/29/2008 | WO2008064094A2 Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
| 05/29/2008 | WO2008064056A2 Tetracycline repressor and uses thereof |
| 05/29/2008 | WO2008063839A2 Targeted delivery of therapeutic agents with lyophilized matrices |
| 05/29/2008 | WO2008063832A2 S1p signaling and heart disease |
| 05/29/2008 | WO2008063802A2 Suppression of mitochondrial oxidative stress |
| 05/29/2008 | WO2008063773A2 Combinatorial treatment with epidermal growth factor receptor inhibitor molecules and melanoma differentiation associated gene-7 |
| 05/29/2008 | WO2008063760A2 Methods for treating cancer targeting transglutaminase |
| 05/29/2008 | WO2008063586A2 Multicomponent vaccine |
| 05/29/2008 | WO2008063562A2 Materials and methods of introducing genetic material into living cells |
| 05/29/2008 | WO2008062909A1 ENVIRONMENT-RESPONDING siRNA CARRIER USING DISULFIDE-BRIDGED POLYMERIC MICELLE |
| 05/29/2008 | WO2008061370A1 Diagnostic method to detect endometriosis |
| 05/29/2008 | WO2008043099A3 Hybrid pacing system |
| 05/29/2008 | WO2007137237A9 Treatment of protein misfolding |
| 05/29/2008 | WO2007075371A3 Protein modulators of resistance to alkylating agents |
| 05/29/2008 | WO2006137597A9 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
| 05/29/2008 | US20080125465 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 05/29/2008 | US20080125391 administering to a mammal harboring a tumor which expresses HALRs, a Sindbis virus vector to treat the tumor, and the vector has not been modified to target a tumor-specific cellular determinant, has a preferential affinity for HALRs, a Sindbis virus E2 HALR binding domain; ganciclovir; gene therapy |
| 05/29/2008 | US20080125388 treating or preventing a condition of excessive cell death by administering a nucleic acid molecule encoding a protein having CPG15-2 biological activity; acts as survival factor by rescuing hippocampal and cortical neurons from cell death; inhibiting activity of CPG15-2 for cancer treatment |
| 05/29/2008 | US20080125387 Administering vector system that directs regulated erythropoietin (Epo) gene therapy in a manner that physiologically corrects the hematocrit levels in a patient in need of anemia treatment |
| 05/29/2008 | US20080125386 RNA interference agents for therapeutic use |
| 05/29/2008 | US20080125369 Soluble t cell receptors |
| 05/29/2008 | US20080124803 cDNA Corresponding to the antigenome of nonsegmented negative stranded RNA viruses and process for the production of such viruses |
| 05/29/2008 | US20080124370 to treat inflammation and pain in a subject using small interfering RNA (siRNA) molecules targeted to either TNF alpha , IL1, IL6 and other pro-inflammatory cytokines; implantable depots to deliver a siRNA molecule to intervertebral discs or articulating joints |
| 05/29/2008 | US20080124360 Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| 05/29/2008 | US20080124358 Chemically conjugating a peptide of interest to a heterologous peptide that has been expressed on the coat protein of a cowpea mosaic virus to generate a conjugate and administering the conjugate to a host animal to increase the level of TH1-type immune response |
| 05/29/2008 | US20080124357 vector may contain at least one heterologous nucleic acid molecule(s), expresses in vivo in the animal VSV antigen(s), immunogen(s) or epitope(s) thereof, e.g., VSV G protein and/or VSV N protein and/or VSV M protein |